ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

3. ACQUISITION (Tables)

3 Months Ended

Mar. 31, 2018

	Three Months Ended March 31,
	2017
Revenues:
As reported	$	2,628,871
Proforma	$	13,722,649

Net loss
As reported	$	(6,536,963	)
Proforma	$	(12,773,860	)

Basic and diluted net loss per share:
As reported	$	(0.51	)
Proforma	$	(0.50	)